|
| |
JAK2
Gene Information from Publications |
| Publication Link |
Summary of findings |
| 18055983 |
Eight mutation-positive cases were identified, including one with a previously undescribed mutant JAK2 exon 12 allele and another with biallelic involvement. |
| 18056003 |
JAK2 exon 12 mutations were detected in 4 out of 20 polycythemia vera and idiopathic erythrocytosis V617F-negative patients and were only present in the myeloid lineage |
| 18230964 |
observations suggest that the clinical phenotype of the JAK2 exon 12 mutation is partly different from that of the JAK2 V617F mutation |
| 18092959 |
Higher haemoglobin and lower platelet levels in the JAK2 V617F mutation positive essential thrombocythemia patients. |
| 18216871 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18239666 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18270328 |
Observational study of gene-disease association. (HuGE Navigator) |
| 18294066 |
Observational study of genetic testing. (HuGE Navigator) |
| 18297539 |
Observational study of genotype prevalence. (HuGE Navigator) |
| 18306358 |
Observational study of genotype prevalence. (HuGE Navigator) | →View more information from publications. |
Recent Publications on JAK2: |  |
Correlation of JAK2 V617F mutant allele quantitation with clinical presentation and type of chronic myeloproliferative neoplasm.
Activating JAK2 V617F mutation is present in many patients with chronic... | 3rd November, 2009
| Clinical Pathology Department, William Beaumont Hospital, Royal Oak,
| Ann Clin Lab Sci. 2009 Fall;39(4):345-50.
|
Hormonal control of luminescence from lantern shark (Etmopterus spinax) photophores.
The velvet belly lantern shark (Etmopterus spinax) emits a blue... | 3rd November, 2009
| Laboratory of Marine Biology, Catholic University of Louvain, B-1348
| J Exp Biol. 2009 Nov;212(Pt 22):3684-92.
DOI Direct Link |
JAK2 Gets Histone H3 Rolling.
Activation of JAK2 is implicated in normal hematopoiesis as well as... | 3rd November, 2009
| Department of Medicine, Brigham and Women's Hospital and Harvard Medical
| Cancer Cell. 2009 Nov 6;16(5):365-6.
DOI Direct Link |
JAK2 V617F Mutation Detection: Laboratory Comparison of Two Kits Using RFLP and qPCR.
Aim: The JAK2 V617F mutation has been implicated in a variety of diseases... | 3rd November, 2009
| 1 Department of Pathology & Laboratory Medicine, American University of
| Genet Test Mol Biomarkers. 2009 Oct 30.
DOI Direct Link |
Expression of estrogen receptor alpha increases leptin-induced STAT3 activity in breast cancer cells.
Adipositas correlates with an enhanced risk of developing malignant... | 31st October, 2009
| Junior Research Group, Paul-Ehrlich-Institute, Langen, Germany.
| Int J Cancer. 2009 Oct 28.
DOI Direct Link |
→View more research publications. |
Press Releases on JAK2:
|
 |
| TargeGen Announces Successful Completion of Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients |
22nd October, 2009 |
TargeGen, Inc. |
SAN DIEGO, Oct. 22 /PRNewswire/ -- TargeGen, Inc. today announced that the Company has successfully completed a 59 patient, multicenter clinical trial of TG101348, an oral, potent,
|
| New Chromosomal Abnormality Identified in Leukemia Associated with Down Syndrome |
18th October, 2009 |
St. Jude Children's Research Hospital |
Study led by St. Jude Children's Research Hospital investigators expands understanding of acute lymphoblastic leukemia in children with Down syndrome, fueling hope
|
| Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia |
19th June, 2009 |
Cephalon, Inc. |
FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients
|
| Biomedical Sciences Companies Expanding in Asia Invested More Than US$500 Million in Singapore |
18th May, 2009 |
|
ATLANTA, May 18 /PRNewswire/ -- Global biomedical sciences companies invested more than US$500 million in
Singapore in the year 2008. This rides on Singapore's strong scientific
|
| TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin |
14th May, 2009 |
TargeGen, Inc. |
SAN DIEGO, May 14 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly
|
JAK2 results (if any) from reagent suppliers | 
|
Search Bioportfolio and other Life Science Sites for JAK2,
or search for JAK2 on BioPortfolio's antibody search engine.
This page has been viewed 1112 times
Recent Search Terms used to find this page: jak2 trial TG101348 | Jak 2 inhibitor October 2009 2009 | ctll-2 lausanne 2009 | Janus kinase 2 | JAK2 2009 | phosphorylated jak2 tyr 1007 1008 | phosphorylated jak2 tyr 1007 1008 | clinical trials JAK2 gene | jack 2 gene | .
Resources from the NCBI used on this page, NCBI's standard disclaimer applies.
|
